Windward Bio Group AG
Biological Products, (No Diagnostic Substances), SIC 2836 · Incorporated in Switzerland
Follow- Filed
- Oct 23, 2026
- Pages
- 313
- Underwriters
- 4
Road to listing
91 days from first draft to public filing- Draft submittedJul 24 · DRSA first draft of the registration statement, sent to the SEC in confidence.0001193125-26-316178
- Draft amendedAug 27 · DRS/A0001193125-26-371520
- Draft amendedSep 21 · DRS/A0001193125-26-396830
- Draft amendedOct 13 · DRS/A0001193125-26-420463
- Filed in publicOct 23 · F-1The registration statement, public for the first time.0001193125-26-430315
- Price range setNot yet · F-1/AAn amendment fills in the price range and the number of shares.
- RoadshowNov 7 at the earliestA company that filed drafts in confidence must file in public at least 15 days before its roadshow begins.
- EffectiveNot yet · EFFECTThe SEC declares the registration statement effective, and the shares can be sold.
- PricedNot yet · 424B4The final prospectus, with the price the shares sold at.
- First tradeNot yet · WWBThe shares open on the exchange, and the desk covers the company in full.
The company sent the SEC 4 drafts in confidence over 91 days, then filed in public on October 23, 2026. Its roadshow can begin November 7, 2026 at the earliest, 15 days after the public filing. The dashed stops are still to come.
Cash
Jun 30, 2026p. F-34
Total assets
Jun 30, 2026p. F-34Liabilities $25.01M
Reading
Thaler Agent, each line on its passageBalance sheet
As filed, in the prospectus’s own lines.
| Line | Jul 5, 2024 | Dec 31, 2024 | Dec 31, 2025 | Jun 30, 2026 |
|---|---|---|---|---|
| Cash and cash equivalents | ||||
| Current financial assets | — | — | ||
| Prepaid expenses | — | |||
| Other current assets | — | — | ||
| Total current assets | ||||
| Property, plant and equipment | — | — | ||
| Intangible assets | — | — | ||
| Right-of-use assets | — | — | ||
| Non-current financial assets | — | — | ||
| Total non-current assets | — | — | ||
| Total assets | ||||
| Trade payables | — | |||
| Other payables | — | — | ||
| Accrued expenses | — | |||
| Current lease liabilities | — | — | ||
| Other current liabilities | — | — | ||
| Total current liabilities | — | |||
| Net pension liabilities | — | — | ||
| Non-current lease liabilities | — | — | ||
| Derivative warrant liability | — | — | — | |
| Total non-current liabilities | — | — | ||
| Total liabilities | — | |||
| Share capital | ||||
| Treasury shares | — | — | ||
| Reserves | — | — | ||
| Accumulated losses | — | |||
| Total equity | ||||
| Total equity and liabilities | ||||
| Cash, cash equivalents and marketable securities | — | — | — |
Read from the prospectus’s tables, merged into one statement: the audited financial statements first, every other table checked against them.
From SEC EDGAR · Form F-1 · 0001193125-26-430315 · filed October 23, 2026